|
COPYRIGHT 2002 International Medical News Group
ANAHEIM, CALIF. -- The ADMIRAL study strengthens the case for using abciximab in conjunction with stent procedures for diabetic patients with acute myocardial infarctions.
Data from the 300-patient ADMIRAL (Abciximab before Direct angioplasty and stenting in MI Regarding Acute and Long-term follow-up) study, presented by Dr. Gilles Montalescot at the annual scientific sessions of the American Heart Association, show that abciximab reduces the risk of a second MI, death, and the need for target vessel revascularization in diabetics undergoing primary stenting.
The risk for restenosis and...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
